EP1076647A2 - Antipsychotisch wirkende indolyl-derivate - Google Patents

Antipsychotisch wirkende indolyl-derivate

Info

Publication number
EP1076647A2
EP1076647A2 EP99918863A EP99918863A EP1076647A2 EP 1076647 A2 EP1076647 A2 EP 1076647A2 EP 99918863 A EP99918863 A EP 99918863A EP 99918863 A EP99918863 A EP 99918863A EP 1076647 A2 EP1076647 A2 EP 1076647A2
Authority
EP
European Patent Office
Prior art keywords
group
pharmaceutically acceptable
compound
indol
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99918863A
Other languages
English (en)
French (fr)
Inventor
Michael Gerard Kelly
Young Hee Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of EP1076647A2 publication Critical patent/EP1076647A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention concerns a series of novel ⁇ -hydroxy aryloxypropylamines which are effective pharmaceuticals for the treatment of conditions related to or affected by the dopamine D2 receptor and also by the serotonin 1A receptor subtype.
  • the compounds are particularly useful for the treatment of schizophrenia and related psychotic disorders and other conditions such as Parkinson's disease and Alzheimer's disease.
  • This invention relates to novel indolyl derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in therapy.
  • the compounds are useful for the treatment of psychotic disorders, particularly schizophrenia, by virtue of their ability to antagonize the dopamine D2 receptor.
  • the present invention also provides compounds that are antagonists and agonists at the 5-HT1A receptor subtype and thus compounds of this invention may be used to treat Alzheimer's Disease, Parkinson's Disease, depression and anxiety.
  • R, and R 2 are each independently selected from H, OH, F, Cl, Br, I, 1 to 6 carbon alkyl or alkenyl, 1 to 6 carbon alkoxy, aryl, arylalkyl, aralkyloxy, OR 5 , nitro.
  • R 3 represents a group selected from hydrogen, a 1 to 6 carbon alkyl, a 1 to 4 carbon alkoxy or a halogen;
  • R 4 represents a group selected from hydrogen, 1 to 6 carbon alkyl or R 5 ;
  • R 5 is CH 2 Ph in which the phenyl ring can be optionally substituted by a group selected from OMe, halogen, CF 3 ;
  • aryl as used in the definitions of R, and R 2 indicates phenyl, or pyridine groups, optionally substituted by from 1 to 3 substitutents selected from halogen, C,-C 6 alkyl, C,-C 6 alkoxy, -S-C,-C 6 alkyl, -CN, -OH, -NO 2 or -CF 3 .
  • the most preferred aryl group is phenyl, optionally substituted as just described.
  • the most preferred arylalyl group in the definitions above is benzyl and the preferred aralkyloxy group is benzyloxy.
  • the pharmaceutically acceptable salts are the acid addition salts which can be formed from a compound of the above general formula and a pharmaceutically acceptable inorganic acid such as phosphoric, sulfuric, hydrochloric, hydrobromic citric, maleic. fumaric, acetic, lactic or methanesulfonic acid.
  • a pharmaceutically acceptable inorganic acid such as phosphoric, sulfuric, hydrochloric, hydrobromic citric, maleic. fumaric, acetic, lactic or methanesulfonic acid.
  • the phenol 1 is reacted with an epoxide of formula 2 to afford the required product.
  • the starting phenol may be commercially available or can be readily obtained by those practiced in the art of organic synthesis.
  • the epoxide 2 is available for example, from the reaction of an amine of formula 4 with optically active or racemic epichlorohydrin or glycidyl tosylate.
  • the epoxide 3 can be obtained from the reaction of a phenol of formula 1 with optically active or racemic epichlorohydrin or glycidyl tosylate. Reaction of this compound with an amine of formula 4 affords the required product. The product can then be used to form a pharmaceutically acceptable addition salt.
  • Compounds of the present invention bind with very high to the 5-HT1A receptor and the dopamine D2 receptor and consequently, they are useful for the treatment of central nervous system disorders such as schizophrenia, depression, anxiety, including generalized anxiety, sleep disorders, sexual dysfunction, alcohol and cocaine addiction, and related problems in addition to the treatment of Alzheimer's disease, Parkinson's disease, obesity and migraine.
  • the present compounds can also be used in regimens to increase cognition enhancement.
  • This invention includes methods of treating in mammals each of these maladies, as well as a method of increasing cognition enhancement, the methods comprising administering to a mammal in need thereof an effective amount of one or more of the compounds of this invention, or a pharmaceutically acceptable salt thereof.
  • the therapeutically effective dosage to be used in the treatment of a specific psychosis must be subjectively determined by the attending physician. Variables involved include the specific psychosis or state of anxiety and the size, age and response pattern of the patient.
  • the novel method of the invention for treating conditions related to or are affected by the reuptake of serotonin comprise administering to warm-blooded animals, including humans, an effective amount of at least one compound of this invention or a non-toxic, pharmaceutically acceptable addition salt thereof.
  • the compounds may be administered orally, rectally, parenterally. or topically to the skin and mucosa. The usual daily dose is depending on the specific compound, method of treatment and condition treated.
  • An effective dose of 0.01 - lOOOmg/Kg may be used for oral application, preferably 0.5 - 500 mg/Kg, and an effective amount of 0.1 - 100 mg/Kg may be used for parenteral application, preferably 0.5 - 50 mg/Kg.
  • the present invention also includes pharmaceutical compositions containing a compound of this invention, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.
  • Applicable solid carriers or excipients can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintergrating agents or an encapsulating material.
  • the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain up to 99% of the active ingredient.
  • Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs.
  • the active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
  • suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g.
  • cellulose derivatives preferably sodium carboxymethyl cellulose solution
  • alcohols including monohydric alcohols and polyhydric alcohols e.g. glycols
  • oils e.g. fractionated coconut oil and arachis oil
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.
  • the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules.
  • the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
  • the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids.
  • the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
  • the affinity of drugs for the dopamine receptor was established by testing the claimed compound's ability to displace [ 3 H]-Spiperone binding in CHO cells stabily transfected with the human dopamine D2 receptor.
  • CHO cells expressing the human dopamine D2 receptor were cultured in suspension by expansion (every 3 - 4 days) in a serum free media to provide approximately 7.5 x 10 5 cells/ml.
  • the cells were harvested by centrifugation (900 x g for 10 min.), resuspended in half volume of IX dulbecco PBS solution at pH 7.4, and after a further recentrifugation, the cell pellet was resuspended in 50 mM Tris.HCl (pH 7.4) containing 1.5 M CaCl 2 , 5.0 mM EDTA, 5.0 mM KC1, 120 mM NaCl, 1.0 mM PMSF and 1.0 mg % leupeptin.
  • the cells were homogenized, centrifuged at 40,000 x g for 30 minutes and resuspended in fresh buffer (10 ml), and the process repeated twice. The final pellet was suspended in a volume of 50.0 mM Tris.HCl sufficient to give a protein concentration of 125.0 ⁇ g/ml of membrane suspension.
  • the binding assay is performed in a 96 well microtiter plate. 100 ⁇ l of buffer is added to the wells, and those receiving a displacer for nonspecific binding (NSB) assessment or test compounds receive 80 ⁇ l of incubation buffer.
  • NBS nonspecific binding
  • 89 - 100 Ci mmole is used as ligand and 0.5 nM in 20 ⁇ l volume is added to all wells, followed by the addition of the displacer D-butaclamol (l ⁇ M in 20 ⁇ l) for nonspecific binding determination.
  • the reaction is initiated by the addition of 80 ⁇ l of the tissue membrane, and after 120 minutes at room temperature the wells are harvested using a Brandell® Harvester onto glass fiber filter presoaked in 0.1% polyethylimine. After washing three times with cold 50 mM Tris.HCl, the filter mat is oven dried and sealed in an envelope with melted multitex for scintillation counting in a Wallac 1205 BetaPlate Counter. The data is analyzed and Ki values are computed for active compounds. Using this assay, the following Ki's were determined for a series of standard D2 receptor ligands.
  • the binding assay is performed in a 96 well microtiter plate in a total volume of 250 ⁇ L. Non-specific binding is determined in the presence of 10 mM 5HT, final ligand concentration is 1.5 nM. Following a 30 minute incubation at room temperature, the reaction is terminated by the addition of ice cold buffer and rapid filtration through a GF/B filter presoaked for 30 minutes in 0.5% PEL Compounds are initially tested in a single point assay to determine percent inhibition at 1, 0.1, and 0.01 mM, and Ki values are determined for the active compounds.
  • the title compound is prepared from the reaction of l-(indole-4-oxy)-2,3- epoxypropane (2.0 mmole) and l-(lH-benzimidazole-4-yl)piperazine (2 mmole) according to the above procedures.
  • the title compound is prepared from the reaction of l-(indole-4-oxy)-2,3- epoxypropane (2.0 mmole) and l-(lH-2-oxindol-4-yl)piperazine (2 mmole) using the procedures outlined in the previous examples.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
EP99918863A 1998-04-29 1999-04-28 Antipsychotisch wirkende indolyl-derivate Withdrawn EP1076647A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6912998A 1998-04-29 1998-04-29
US69129 1998-04-29
PCT/US1999/009132 WO1999055672A2 (en) 1998-04-29 1999-04-28 Antipsychotic indolyl derivatives

Publications (1)

Publication Number Publication Date
EP1076647A2 true EP1076647A2 (de) 2001-02-21

Family

ID=22086935

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99918863A Withdrawn EP1076647A2 (de) 1998-04-29 1999-04-28 Antipsychotisch wirkende indolyl-derivate

Country Status (7)

Country Link
EP (1) EP1076647A2 (de)
JP (1) JP2002513001A (de)
CN (1) CN1155567C (de)
AR (1) AR015036A1 (de)
AU (1) AU3667899A (de)
CA (1) CA2330452A1 (de)
WO (1) WO1999055672A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1164574C (zh) * 1999-05-24 2004-09-01 三菱制药株式会社 苯氧基丙胺类化合物
AU1057401A (en) * 1999-11-11 2001-06-06 Senju Pharmaceutical Co., Ltd. Pancreatitis remedies
AU2049601A (en) 1999-12-20 2001-07-03 Eli Lilly And Company Benzofuran derivatives
AU1930901A (en) * 1999-12-20 2001-07-03 Eli Lilly And Company Azabicyclo(3.2.1)octane derivatives
AR027134A1 (es) * 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
HUP0302761A2 (hu) * 2000-11-14 2003-12-29 Merck Patent Gmbh. Kombinált szelektív dopamin D2 receptor antagonista és 5-HT1A receptor agonista hatású vegyületek alkalmazása gyógyszerkészítmények előállítására
WO2002048105A2 (en) 2000-11-16 2002-06-20 Wyeth Aryloxy piperidinyl derivatives for the treatment of depression
WO2002042297A1 (en) * 2000-11-27 2002-05-30 Mitsubishi Pharma Corporation Piperidine compounds and medicinal use thereof
WO2003002552A1 (en) * 2001-06-29 2003-01-09 H. Lundbeck A/S Novel indole derivatives
AU2002355170B2 (en) 2001-07-26 2007-06-07 Merck Patent Gmbh Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
RU2007101544A (ru) 2004-06-17 2008-08-10 Уайт (Us) Антагонисты рецепторов высвобождающего гонадотропин гормона
RU2007101509A (ru) 2004-06-17 2008-07-27 Уайт (Us) Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин
ES2331144T3 (es) 2004-11-26 2009-12-22 Janssen Pharmaceutica Nv Derivados de isoxazolina-indol con actividad antipsicotica y ansiolitica mejorada.
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
BRPI0613430A2 (pt) 2005-07-13 2011-01-11 Hoffmann La Roche compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica
WO2008055808A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
JP2011529090A (ja) 2008-07-28 2011-12-01 江蘇国華投資有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
CN101973925B (zh) * 2010-10-15 2012-03-28 中国药科大学 具有抗炎活性的2-吲哚酮类化合物、其制备方法及医药用途
PL395469A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
CN102871978B (zh) * 2012-10-19 2014-04-09 河北仁合益康药业有限公司 一种左舒必利片及其制备方法
CN116554145B (zh) * 2022-01-29 2025-06-03 江苏恩华药业股份有限公司 芳烷基-4-(1h)吲哚基哌嗪衍生物、其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335126A (en) * 1977-03-10 1982-06-15 Degussa Aktiengesellschaft 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
FR2567884B1 (fr) * 1984-07-19 1987-03-06 Roussel Uclaf Nouveaux derives de l'indole, leur preparation, leur application comme medicaments et les compositions les renfermant
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9955672A2 *

Also Published As

Publication number Publication date
WO1999055672A2 (en) 1999-11-04
AU3667899A (en) 1999-11-16
CA2330452A1 (en) 1999-11-04
AR015036A1 (es) 2001-04-11
WO1999055672A3 (en) 2000-01-20
CN1155567C (zh) 2004-06-30
JP2002513001A (ja) 2002-05-08
CN1307562A (zh) 2001-08-08

Similar Documents

Publication Publication Date Title
EP1076647A2 (de) Antipsychotisch wirkende indolyl-derivate
CN1229345C (zh) N－(吲哚羰基)哌嗪衍生物
US6689792B2 (en) Antipsychotic indolyl derivatives
KR20080114688A (ko) 5-히드록시트립타민 수용체에 대한 리간드로서의 술포닐 치환된 1ｈ-인돌
KR20050010861A (ko) 중추 신경계 장애의 치료를 위한 5-ｈｔ6-수용체조절제로서 1-설폰일-4-아미노알콕시 인돌 유도체
NZ519692A (en) Phenylpiperazinyl, -piperidinyl or -tetrahydropyridinyl derivatives
KR100792186B1 (ko) 4-페닐-1-피페라지닐, -피페리디닐 및 -테트라히드로피리딜유도체
EP1663981B1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
EP0678090B1 (de) Piperazinderivate
CN1372545A (zh) 吲哚衍生物
CN1043764C (zh) 作为5－ht1a拮抗剂的双环甲酰胺
MXPA00010455A (en) Antipsychotic indolyl derivatives
US5166157A (en) Naphthyl piperazines useful as 5-HT1A receptor ligands
EP0687257B1 (de) 4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten
US5162321A (en) 1-naphthyl piperazines useful as 5-HT1A receptor ligands
EP1751105B1 (de) Piperazinderivate von alkyloxindolen
NZ540801A (en) 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
MXPA01008842A (es) Derivados n-substituidos de imida con actividad serotonergica

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001004

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001004;LT PAYMENT 20001004;LV PAYMENT 20001004;RO PAYMENT 20001004;SI PAYMENT 20001004

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH

17Q First examination report despatched

Effective date: 20030611

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050518

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1032400

Country of ref document: HK